Nonprescription opioid use during opioid agonist therapy is not uncommon. The response should be supportive and not punitive. Increasing the frequency of follow-up enhances monitoring, supports adherence, and prevents relapse.

Toronto Notes 2023 – Psychiatry, “Substance Use Disorders”:

“Patients who relapse during opioid agonist treatment benefit from closer monitoring and increased support, including more frequent follow-up and psychosocial interventions.”

MCCQE1 Objectives (Psychiatry > 71-5: Substance Use and Addiction):

“Candidates must manage relapses in opioid use by optimizing follow-up and support, not by discontinuing or reducing therapy prematurely.”

Tapering or discontinuing therapy (A, E) risks destabilizing treatment. Removing take-home doses (B) may be warranted later but not first. Cannabinoids (D) are not first-line adjuncts.

====================================================